RxDoctor Payments Data

James Bruno, MD

Neurology · Stony Brook, NYNPI 1750436879

Payments from drug & device makers

$14,970in general payments, 2019–2025

Across 214 payments — averaging $69.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$6K
  • SK Life Science, Inc.$1K
  • UCB, Inc.$1K
  • Livanova USA, Inc.$971
  • Teva Pharmaceuticals USA, Inc.$625
  • Harmony Biosciences LLC$538
  • plus $4K from 28 others

What the payments were for

  • Speaking & faculty fees$5,82139%
  • Travel & lodging$7765%
  • Food & beverage$7,99553%
  • Education$3773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,970 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$203,408
Medicare patients
514
Services billed
1,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate44$52,462
XcopriCenobamate36$38,472
BriviactBrivaracetam13$17,234
FycompaPerampanel12$14,737
VimpatLacosamide12$14,626
Levetiracetam94$3,830
Lacosamide40$3,743
CarbatrolCarbamazepine12$3,041
Gabapentin162$2,258
Topiramate105$1,634
Pregabalin34$1,339
Clonazepam21$1,297
Oxcarbazepine22$1,086
Donepezil Hcl97$865
Divalproex Sodium35$709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$6,340$52,46244 claims
SK Life Science, Inc.Xcopri$1,260$38,47236 claims
UCB, Inc.Briviact, Vimpat$1,163$31,86025 claims
Eisai Inc.Fycompa$108$14,73712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →